The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes

Table 2

Side effects as total scores on UKU-24. LOCF analysis.

UKU-24	Active T-PEMF	Sham T-PEMF
	(𝑁=21)	(𝑁=19)
Baseline	12.3 (2.6)	13.5 (2.3)
week 1	11.4 (3.4)	12.2 (2.7)
week 2	10.0 (3.4)	11.2 (2.9)
week 3	9.7 (3.1)	11.1 (2.4)
week 4	9.0 (3.0)	9.8 (2.1)
week 5	8.6 (3.8)	10.2 (2.3)